Navigation Links
Bayer CropScience Debuts Serenade Optimum to Help Growers Control Tough Diseases and Combat Resistance
Date:10/21/2013

Reno, Nev. (PRWEB) October 21, 2013

Today during the 39th Annual CAPCA Conference, Bayer CropScience introduced Serenade® Optimum fungicide and bactericide, its newest innovation for horticulture growers. An excellent addition to a complex disease management program, Serenade Optimum gives growers a new tool to help win the battle against fungal and bacterial diseases while fighting resistance.

“As a global market leader in crop protection, we continuously invest in innovations for new technologies that improve the health, quality and yield of horticulture crops,” said Rob Schrick, Strategic Business Management Lead – Horticulture, Bayer CropScience. “With the addition of Serenade Optimum, we further our commitment to delivering innovative solutions that aid growers in producing quality crops.”

Based on a unique patented strain of Bacillus subtilis (QST 713), Serenade Optimum works in multiple ways to provide effective contact control or suppression of problematic fungal and bacterial diseases. The fungicide’s novel, multi-site mode-of-action makes it very difficult for diseases to develop resistance, empowering growers with a new tool to combat fungicide resistance and enhance existing integrated disease management programs.

Serenade Optimum has a four-hour re-entry internal, a zero-day pre-harvest interval, and is exempt from the requirements of residue tolerance. It is part of a collection of biological fungicides and insecticides from Bayer CropScience that give growers more options in their integrated disease management programs to help fight resistance and optimize the marketability of their crops.

Serenade Optimum is available for use on grapes, leafy and fruiting vegetables, strawberries and potatoes, and is highly effective against fungal diseases, such as Botrytis and Sclerotinia, and bacterial diseases, such as Xanthomonas and Erwinia.

To learn more about Serenade Optimum please visit http://www.bayercropscience.us/products/fungicides/serenade-optimum/. You can also follow and share with us on Twitter @Bayer4CropsUS or connect on the Bayer CropScience social media hub, Bayer Connect.

© 2013 Bayer CropScience LP, 2 T.W. Alexander Drive, Research Triangle Park, NC 27709. Always read and follow label instructions. Bayer, the Bayer Cross and Serenade are registered trademarks of Bayer. For product information call toll-free 1-866-99-BAYER (1-866-992-2937) or visit our Website at bayercropscience.com.

###

About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care,
agriculture and high-tech materials. This year the company looks back on 150 years of working to fulfill its mission “Bayer: Science For A Better Life”. Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 8,383 million (2012) and is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer CropScience has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 20,800 and is represented in more than 120 countries. This and further news is available at: press.bayercropscience.com.

Contact:
Bayer CropScience Media Hotline, 1-877-879-6162, or

Becca Hogan
External Communications Manager
Bayer CropScience
Tel: (919) 549-2998
Email: becca(dot)hogan(at)bayer(dot)com

Ayanna Luke
Porter Novelli
Tel: (404) 995-4536
Email: ayanna(dot)luke(at)porternovelli(dot)com

USA-BCS-2013-0291
Find more information at bayercropscience.us.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11247555.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Bayer CropScience Supports 10th Anniversary of United Way Of The Greater Triangle’s Girls’ Leadership Development Initiative
2. Bayer CropScience and the Florida Specialty Crop Foundation Join Together to Fight Citrus Greening
3. Bayer CropScience Adds Three New HBK Seed Varieties for 2014
4. Bayer CropScience Looks to the Future of Farming at 2013 Farm Progress Show
5. Bayer CropScience Commits to Future of Illinois Agriculture, Education and Communities
6. Bayer CropScience and MS Technologies Receive Approval for Balance GT Soybean Technology in the United States
7. Bayer CropScience Adds New Canola Hybrids and Traits
8. American Museum of Agriculture Changes Name to Reflect Bayer CropScience’s Agriculture Tradition and World-Class Technology
9. Bayer CropScience Sponsors U.S. Delegates at Inaugural Global Youth Ag Summit
10. Bayer CropScience Celebrates 150 Years of Innovation; Asks for 150 Perspectives on the Future of Farming
11. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):